Myelodysplastic Syndrome/Acute Myeloid Leukemia

Myelodysplastic Syndrome/Acute Myeloid Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

24 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02220985	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	completed	Phase 2	84	Fred Hutchinson Cancer CenterOTHER	1	Jun 1, 2026	clinicaltrials
NCT03092674	Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	completed	Phase 2 / Phase 3	76	National Cancer Institute (NCI)NIH